The Dangers of Electronic Cigarettes: A Call for Regulation

Aug.29.2022
The Dangers of Electronic Cigarettes: A Call for Regulation
Electronic cigarette use in Brazil raises concerns despite the country's effective tobacco control policies. Potential health risks exist.

In recent years, electronic cigarettes have gained a lot of attention online, causing many people to have doubts about their safety. Despite Brazil's ban on the production and sale of electronic cigarettes since 2009, their usage has significantly increased in recent years due to their easy availability on both websites and physical storefronts.


Brazil is known as a global model for tobacco control public policy. Policies implemented over the years from 1989 to 2019 have reduced tobacco consumption among those aged 18 and over by about 60%. Some of these policies prevented children and adolescents from accessing tobacco products, thus preventing them from smoking. However, unlike all efforts to reduce smoking through public health, a new smoking trend emerged: electronic cigarettes. This includes a nicotine release device, whose first prototype was created in Pennsylvania in 1963, but it was never commercialized. In 2003, electronic cigarettes were created in China and spread around the world a decade later after a major tobacco industry company acquired a patent for them.


Many young people are drawn to the various formats, designs, and flavors of electronic cigarettes, making up a significant proportion of e-cigarette users. Research shows that in Brazil, one in five young people aged 18-24 have already used e-cigarettes. Additionally, 80% of those who use e-cigarettes are between the ages of 18 and 34. However, studies indicate that apart from nicotine, the aerosol may also contain other irritants and toxic substances such as formaldehyde, acrolein, diethylene glycol, acetaldehyde, benzene, and low doses of carcinogens. Tests on cells, tissues, and small animals exposed to liquids from different brands of e-cigarettes indicate that they are toxic to neurological, respiratory, and cardiovascular cells and may have adverse effects and cause birth defects during critical stages of fetal development.


The safety of electronic nicotine delivery systems has not been scientifically proven. In fact, the amount of nicotine dispensed by different e-cigarette devices can vary greatly, exposing consumers to much higher doses of the substance than traditional cigarettes. Reports have linked multiple incidents of severe burns, dismemberment and even death to explosions of e-cigarette batteries, dependent on the device's position at the time of detonation.


Although there is a lack of research evaluating the long-term consequences of inhaled substances from these devices, it is well-known that in the short-term, they may trigger or exacerbate symptoms of previously existing conditions such as coughing, asthma, chronic obstructive pulmonary disease (COPD), and hypertension. Additionally, in 2019, a series of severe cases of lung illness related to the use of electronic cigarettes, known as EVALI, was reported in the United States. By 2020, these cases resulted in over 2,800 hospitalizations, with many in intensive care units, and 68 deaths. The majority of cases were in young people, with one patient requiring a lung transplant.


Although the tobacco industry has attempted to convey the idea that e-cigarettes can aid in quitting smoking, this is not a good strategy. E-cigarette use operates through the same mechanism as traditional cigarettes, providing the brain with a nicotine rush. This explains why over 80% of those who use e-cigarettes to quit smoking still rely on nicotine (and e-cigarettes) after a year of follow-up. Scientifically proven and effective behavioral and pharmacological therapies are available to help quit smoking.


Since 2009, the use of electronic cigarettes has been prohibited in Brazil and will continue to be banned. However, children and teenagers are still able to obtain them, and the rate of experimentation is increasing daily. It is time to acknowledge that electronic cigarettes are not just vaporizers and to implement monitoring and restrictions on their sales.


Statement:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The compilation of this article is only intended for industry discussion and research.


Due to limitations in our translation abilities, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign related statements and positions.


The compilation of information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
From Border-Logistics Insiders to Retail Service Stations, Australia Mounts a Sweeping Crackdown on the Illicit Nicotine Trade as iGET Vapes Surface in A$80 Million Crime Networks
From Border-Logistics Insiders to Retail Service Stations, Australia Mounts a Sweeping Crackdown on the Illicit Nicotine Trade as iGET Vapes Surface in A$80 Million Crime Networks
Australian authorities have disclosed two major enforcement actions that go beyond product seizures and retail closures to examine how illicit tobacco and vape networks operate. On Aug. 14, the Multi Agency Strike Team said seven people had been charged and two criminal networks were valued by authorities at a combined A$80 million, or about US$56.8 million. Investigators allege the groups used bonded warehouses, freight businesses and “trusted insiders” in legitimate industries to circumvent border controls. In a separate operation on Aug. 11, more than 100 service stations were targeted as authorities sought information on illicit tobacco importation, distribution networks and the movement of sales proceeds.
Aug.17
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03